{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:20:04Z","timestamp":1792408804746,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.annonc.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T17:12:45Z","timestamp":1589562765000},"page":"1207-1215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Characterization of on-target adverse events caused by TRK inhibitor therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"D.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Flory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Gounder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.N.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Glade-Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kaplanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-9061","authenticated-orcid":false,"given":"A.","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.006_bib2","first-page":"ix173","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.05.006_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.006_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"CT127","DOI":"10.1158\/1538-7445.AM2019-CT127","article-title":"Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)","volume":"79","author":"Hyman","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.05.006_bib6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.05.006_bib7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A\u00a0next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.05.006_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(94)90048-5","article-title":"Functions of the neurotrophins during nervous system development: what the knockouts are teaching us","volume":"77","author":"Snider","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/neu.480251107","article-title":"The Trk family of neurotrophin receptors","volume":"25","author":"Barbacid","year":"1994","journal-title":"J\u00a0Neurobiol"},{"key":"10.1016\/j.annonc.2020.05.006_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/368246a0","article-title":"Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk\/NGF receptor gene","volume":"368","author":"Smeyne","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0092-8674(05)80088-1","article-title":"Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death","volume":"75","author":"Klein","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/368249a0","article-title":"Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements","volume":"368","author":"Klein","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.05.006_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0092-8674(94)90378-6","article-title":"Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons","volume":"76","author":"Crowley","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2020.05.006_bib14","doi-asserted-by":"crossref","first-page":"e1900","DOI":"10.1371\/journal.pone.0001900","article-title":"Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates","volume":"3","author":"Lin","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2020.05.006_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nn1336","article-title":"A\u00a0de novo mutation affecting human TrkB associated with severe obesity and developmental delay","volume":"7","author":"Yeo","year":"2004","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.annonc.2020.05.006_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ng0896-485","article-title":"Mutations in the TRKA\/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis","volume":"13","author":"Indo","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.05.006_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0","article-title":"The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1\/nerve growth factor receptor","volume":"182","author":"Greco","year":"2000","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.annonc.2020.05.006_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.006_bib19","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE); 2018. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed October 2, 2019."},{"key":"10.1016\/j.annonc.2020.05.006_bib20","unstructured":"US Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions 2018. Available at: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0. Accessed July 4, 2019."},{"key":"10.1016\/j.annonc.2020.05.006_bib21","unstructured":"US Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC 2019. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed November 12, 2019."},{"key":"10.1016\/j.annonc.2020.05.006_bib22","unstructured":"European Medicines Agency. First \u2018histology-independent\u2019 treatment for\u00a0solid tumours with a specific gene mutation: EMA Press office; 2019.\u00a0Available at: https:\/\/www.ema.europa.eu\/en\/news\/first-histology-independent-treatment-solid-tumours-specific-gene-mutation. Accessed December 10, 2019."},{"key":"10.1016\/j.annonc.2020.05.006_bib23","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1210\/mend.15.10.0706","article-title":"Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity","volume":"15","author":"Rios","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.annonc.2020.05.006_bib24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1053\/j.gastro.2016.12.049","article-title":"Practical use of pharmacotherapy for obesity","volume":"152","author":"Igel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annonc.2020.05.006_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.05.006_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MED.0000000000000516","article-title":"Incretin therapy for diabetes mellitus type 2","volume":"27","author":"Holst","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.annonc.2020.05.006_bib27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2020.05.006_bib28","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1523\/JNEUROSCI.4991-10.2011","article-title":"TrkB (tropomyosin-related kinase B) controls the assembly and maintenance of GABAergic synapses in the cerebellar cortex","volume":"31","author":"Chen","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.annonc.2020.05.006_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cne.20386","article-title":"Phenotype of cerebellar glutamatergic neurons is altered in stargazer mutant mice lacking brain-derived neurotrophic factor mRNA expression","volume":"481","author":"Richardson","year":"2005","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.annonc.2020.05.006_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1474-4422(08)70088-7","article-title":"Management of neurogenic orthostatic hypotension: an update","volume":"7","author":"Low","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annonc.2020.05.006_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archneur.1972.00490140033006","article-title":"Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy in a double-blind study","volume":"27","author":"Cohen","year":"1972","journal-title":"Arch Neurol"},{"key":"10.1016\/j.annonc.2020.05.006_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM197907123010202","article-title":"Mineralocorticoid-induced hypertension in patients with orthostatic hypotension","volume":"301","author":"Chobanian","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.006_bib33","doi-asserted-by":"crossref","first-page":"444P","DOI":"10.1111\/j.1365-2125.1978.tb04616.x","article-title":"Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents","volume":"6","author":"Davies","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.annonc.2020.05.006_bib34","first-page":"527","article-title":"Evaluation and management of orthostatic hypotension","volume":"84","author":"Lanier","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.annonc.2020.05.006_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/papr.12342","article-title":"NGF\/TrkA Signaling as a therapeutic target for pain","volume":"16","author":"Hirose","year":"2016","journal-title":"Pain Pract"},{"key":"10.1016\/j.annonc.2020.05.006_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/humu.1224","article-title":"Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor","volume":"18","author":"Indo","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.annonc.2020.05.006_bib37","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/sj.emboj.7600893","article-title":"NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels","volume":"24","author":"Zhang","year":"2005","journal-title":"EMBO J"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:58:51Z","timestamp":1760335131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420398203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0923753420398203"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of on-target adverse events caused by TRK inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}